Randomized trial demonstrates improved cardiovascular outcomes in elderly with selenium and CoQ10 supplementation, suggesting new protective strategies.
This paper proposes that cardiac mitochondria are governed by the Selenoprotein Axis framework through three specific selenoprotein-dependent mechanisms: (1) TrxR2, the mitochondria-specific thioredoxin reductase selenoenzyme, provides primary redox defense in the cardiac inner mitochondrial membrane; (2) GPx4 suppresses ferroptosis in cardiomyocytes, documented in ischemia-reperfusion injury, doxorubicin cardiotoxicity, and heart failure; (3) T3-mediated coronary artery vasodilation maintains perfusion pressure through selenium-dependent deiodinase T4-to-T3 conversion. The KiSel-10 randomized controlled trial demonstrated 40% reduction in cardiovascular mortality over 12 years from selenium yeast 200mcg plus CoQ10 200mg daily in selenium-insufficient elderly populations. Keshan disease provides historical proof of concept. All claims are hypothesis-level requiring prospective clinical confirmation.
No takes yet. Share an insight, caveat, or question.
Grace Ann (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: